Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robert A. Anders"'
Autor:
Won Jin Ho, Robert A. Anders, Ludmila Danilova, Mark Yarchoan, Elana J. Fertig, Teena Vithayathil, Nilofer S. Azad, Elizabeth M. Jaffee, Qingfeng Zhu, Ana De Jesus-Acosta, Daniel A. Laheru
Publikováno v:
Cancer Immunol Res
Immune-checkpoint therapy has failed to demonstrate meaningful clinical benefit in unselected cases of pancreatic adenocarcinoma (PDAC), but a subset of PDACs are known to upregulate pathways involved in acquired immune suppression. Further delineati
Autor:
Robert A. Anders, Nicolas A. Giraldo, Janis M. Taube, Sanjay S. Patel, Alexander S. Baras, Jérôme Galon, Scott J. Rodig, Lynette M. Sholl, Ashley Cimino-Mathews, David L. Rimm, Tricia R. Cottrell
Publikováno v:
Modern Pathology. 31:214-234
Characterizing the tumor immune microenvironment enables the identification of new prognostic and predictive biomarkers, the development of novel therapeutic targets and strategies, and the possibility to guide first-line treatment algorithms. Althou
Autor:
Jessica Esandrio, Charles G. Drake, Haiying Xu, Ludmila Danilova, Drew M. Pardoll, Janis M. Taube, Hao Wang, Robert A. Anders, Joel C. Sunshine, Genevieve J. Kaunitz, Leslie Cope, Tricia R. Cottrell
Publikováno v:
Proceedings of the National Academy of Sciences. 113
Programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade has led to remarkable and durable objective responses in a number of different tumor types. A better understanding of factors associated with the PD-1/PD-L a
Autor:
Xin-Rong Yang, Yang Xu, Robert A. Anders, Jia Fan, Haibo Bai, Yun Fan Sun, Chaoxin Hu, Qin Feng Zhu, Mehtab Khan, Venugopal Chenna, Hai Xiang Sun, Anirban Maitra
Purpose: To illustrate the prognostic significance of hedgehog (Hh) signaling in patients with hepatocellular carcinoma (HCC) and to evaluate the efficacy of a novel nanoparticle-encapsulated inhibitor of the Hh transcription factor, Gli1 (NanoHHI) u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bb562f8c76ea32e9242a5d5206d53fe
https://europepmc.org/articles/PMC3233659/
https://europepmc.org/articles/PMC3233659/
Autor:
Georgios A. Margonis, Timothy M. Pawlik, Michael A. Choti, Rohan Gupta, Aslam Ejaz, Yuhree Kim, Georgios Karagkounis, Gaya Spolverato, Robert A. Anders, David Cosgrove
Publikováno v:
JAMA Surgery. 150:722
Surgical therapy, often combined with adjuvant systemic chemotherapy, is the best therapeutic option to treat patients with colorectal liver metastasis (CRLM), However, while overall survival (OS) has improved, many patients with CRLM will recur and